Immunomedics Announces Pricing of Public Offering of Common Stock
28 avr. 2020 23h50 HE
|
Immunomedics
MORRIS PLAINS, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Proposed Public Offering Of Common Stock
27 avr. 2020 16h01 HE
|
Immunomedics
MORRIS PLAINS, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Multimedia Update: FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer
23 avr. 2020 08h00 HE
|
Immunomedics, Inc.
First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment of relapsed or refractory...
FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer
22 avr. 2020 11h47 HE
|
Immunomedics
First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment of relapsed or refractory...
CORRECTION - FDA GRANTS FAST TRACK DESIGNATION TO SACITUZUMAB GOVITECAN FOR LOCALLY-ADVANCED OR METASTATIC UROTHELIAL CANCER
07 avr. 2020 09h28 HE
|
Immunomedics
MORRIS PLAINS, N.J., April 07, 2020 (GLOBE NEWSWIRE) -- In a release issued earlier today by Immunomedics, Inc. (Nasdaq:IMMU), the headline was inaccurate. The cancer is accurately described as...
FDA GRANTS FAST TRACK DESIGNATION TO SACITUZUMAB GOVITECAN FOR NEOADJUVANT/ADJUVANT METASTATIC UROTHELIAL CANCER
07 avr. 2020 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., April 07, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
IMMUNOMEDICS ANNOUNCES ASCENT STUDY TO BE STOPPED FOR COMPELLING EFFICACY
06 avr. 2020 08h00 HE
|
Immunomedics
Decision based on recommendation from DSMC following study data review Sacituzumab govitecan has the potential to be the first FDA-approved antibody-drug conjugate for the treatment of metastatic...
IMMUNOMEDICS ANNOUNCES EXECUTIVE LEADERSHIP CHANGES AND THE APPOINTMENT OF HAROUT SEMERJIAN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER
06 avr. 2020 07h50 HE
|
Immunomedics
MORRIS PLAINS, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
IMMUNOMEDICS TO HOST CONFERENCE CALL AND WEBCAST ON APRIL 6, 2020 TO PROVIDE CLINICAL AND CORPORATE UPDATE
03 avr. 2020 17h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., April 03, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
IMMUNOMEDICS PROVIDES COVID-19 BUSINESS CONTINUITY UPDATE, AFFIRMS 2020 STRATEGIC PRIORITIES, AND SHARES R&D AND REGULATORY UPDATE
25 mars 2020 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., March 25, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...